Protica Bio
- Biotech or pharma, therapeutic R&D
- Diagnostics
Protica Bio is redefining precision oncology with a proprietary, AI-powered proteomics platform that identifies predictive biomarkers and novel drug targets with unmatched accuracy. Developed by Prof. Tami Geiger (Weizmann Institute), our platform delivers industry-leading protein coverage (11K) from minimal biopsy samples.
Our lead biomarker for Head & Neck cancer demonstrated an 86% PPV in a multi-center trial, outperforming the current standard (PD-L1, 34%) and is on track to launch as a CLIA LDT in 2026. Three novel drug targets are now in validation.
Backed by a strong scientific team, a growing biobank matched to the high-resolution proteomic database, and a scalable discovery engine, we aim to transform treatment response prediction and accelerate next-gen oncology therapies.
We’re raising seed funding to commercialize our lead product, validate additional drug targets, and expand across new cancer indications in a multibillion-dollar market opportunity.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}